LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Radicicol | 3.33 | uM | LJP5 | 2 | K08 | 72 | hr | 2543 | 2468 | 5578 | 0.4424 | -0.0249 |
| SK-BR-3 | Radicicol | 3.33 | uM | LJP5 | 3 | K08 | 72 | hr | 2543 | 2103 | 5578 | 0.3770 | -0.1451 |
| SK-BR-3 | Radicicol | 3.33 | uM | LJP6 | 1 | K08 | 72 | hr | 2543 | 2176 | 5578 | 0.3901 | -0.1211 |
| SK-BR-3 | Radicicol | 3.33 | uM | LJP6 | 2 | K08 | 72 | hr | 2543 | 2034 | 5578 | 0.3646 | -0.1679 |
| SK-BR-3 | Radicicol | 3.33 | uM | LJP6 | 3 | K08 | 72 | hr | 2543 | 2039 | 5578 | 0.3655 | -0.1662 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 1 | J02 | 72 | hr | 2543 | 4785 | 5578 | 0.8577 | 0.7385 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 2 | J02 | 72 | hr | 2543 | 4809 | 5578 | 0.8620 | 0.7464 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 3 | J02 | 72 | hr | 2543 | 4621 | 5578 | 0.8283 | 0.6845 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 1 | O14 | 72 | hr | 2543 | 5823 | 5578 | 1.0438 | 1.0805 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 2 | O14 | 72 | hr | 2543 | 5434 | 5578 | 0.9741 | 0.9523 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 3 | O14 | 72 | hr | 2543 | 5724 | 5578 | 1.0261 | 1.0479 |
| SK-BR-3 | XL147 | 3.33 | uM | LJP5 | 1 | G08 | 72 | hr | 2543 | 5774 | 5578 | 1.0350 | 1.0644 |
| SK-BR-3 | XL147 | 3.33 | uM | LJP5 | 2 | G08 | 72 | hr | 2543 | 6209 | 5578 | 1.1130 | 1.2077 |
| SK-BR-3 | XL147 | 3.33 | uM | LJP5 | 3 | G08 | 72 | hr | 2543 | 6131 | 5578 | 1.0990 | 1.1820 |
| SK-BR-3 | Saracatinib | 3.33 | uM | LJP6 | 1 | D08 | 72 | hr | 2543 | 4496 | 5578 | 0.8059 | 0.6433 |
| SK-BR-3 | Saracatinib | 3.33 | uM | LJP6 | 2 | D08 | 72 | hr | 2543 | 4629 | 5578 | 0.8298 | 0.6871 |
| SK-BR-3 | Saracatinib | 3.33 | uM | LJP6 | 3 | D08 | 72 | hr | 2543 | 4650 | 5578 | 0.8335 | 0.6940 |
| SK-BR-3 | Selumetinib | 3.33 | uM | LJP6 | 1 | M08 | 72 | hr | 2543 | 5477 | 5578 | 0.9818 | 0.9665 |
| SK-BR-3 | Selumetinib | 3.33 | uM | LJP6 | 2 | M08 | 72 | hr | 2543 | 5495 | 5578 | 0.9850 | 0.9724 |
| SK-BR-3 | Selumetinib | 3.33 | uM | LJP6 | 3 | M08 | 72 | hr | 2543 | 5221 | 5578 | 0.9359 | 0.8822 |
| SK-BR-3 | Sirolimus | 3.33 | uM | LJP6 | 1 | L14 | 72 | hr | 2543 | 3426 | 5578 | 0.6141 | 0.2908 |
| SK-BR-3 | Sirolimus | 3.33 | uM | LJP6 | 2 | L14 | 72 | hr | 2543 | 3416 | 5578 | 0.6123 | 0.2875 |
| SK-BR-3 | Sirolimus | 3.33 | uM | LJP6 | 3 | L14 | 72 | hr | 2543 | 3546 | 5578 | 0.6356 | 0.3303 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 1 | B08 | 72 | hr | 2543 | 5603 | 5578 | 1.0044 | 1.0080 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 2 | B08 | 72 | hr | 2543 | 5861 | 5578 | 1.0506 | 1.0930 |